Jochen Schmitt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7306916/publications.pdf

Version: 2024-02-01

308 15,507 papers citations

19657 26613 61 h-index

107 g-index

396 all docs 396 docs citations

396 times ranked 14388 citing authors

#	Article	IF	CITATIONS
1	The COMET Handbook: version 1.0. Trials, 2017, 18, 280.	1.6	1,128
2	Core Outcome Set–STAndards for Reporting: The COS-STAR Statement. PLoS Medicine, 2016, 13, e1002148.	8.4	404
3	The Psoriasis Area and Severity Index Is the Adequate Criterion to Define Severity in Chronic Plaque-Type Psoriasis. Dermatology, 2005, 210, 194-199.	2.1	353
4	What are the best outcome measurements forÂatopic eczema? A systematic review. Journal of Allergy and Clinical Immunology, 2007, 120, 1389-1398.	2.9	321
5	Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: AÂsystematic review. Journal of Allergy and Clinical Immunology, 2014, 133, 429-438.	2.9	277
6	EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 99-106.	5.7	276
7	Occupational ultraviolet light exposure increases the risk for the development of cutaneous squamous cell carcinoma: a systematic review and meta-analysis. British Journal of Dermatology, 2011, 164, 291-307.	1.5	269
8	The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. Journal of Allergy and Clinical Immunology, 2014, 134, 800-807.	2.9	257
9	Assessment of clinical signs of atopic dermatitis: AÂsystematic review and recommendation. Journal of Allergy and Clinical Immunology, 2013, 132, 1337-1347.	2.9	235
10	A randomized trial of methotrexate versus azathioprine for severe atopic eczema. Journal of Allergy and Clinical Immunology, 2011, 128, 353-359.	2.9	231
11	Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. British Journal of Dermatology, 2011, 164, 415-428.	1.5	219
12	Effect of Intraoperative High Positive End-Expiratory Pressure (PEEP) With Recruitment Maneuvers vs Low PEEP on Postoperative Pulmonary Complications in Obese Patients. JAMA - Journal of the American Medical Association, 2019, 321, 2292.	7.4	216
13	Cyclosporin in the treatment of patients with atopic eczema? a systematic review and meta-analysis. Journal of the European Academy of Dermatology and Venereology, 2007, 21, 070206173308005-???.	2.4	202
14	Is occupational solar ultraviolet irradiation a relevant risk factor for basal cell carcinoma? A systematic review and meta-analysis of the epidemiological literature. British Journal of Dermatology, 2011, 165, no-no.	1.5	189
15	The Harmonizing Outcome Measures for Eczema (HOME) Roadmap: A Methodological Framework to Develop Core Sets of Outcome Measurements in Dermatology. Journal of Investigative Dermatology, 2015, 135, 24-30.	0.7	184
16	Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. British Journal of Dermatology, 2008, 159, 513-526.	1.5	182
17	When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. Journal of the American Academy of Dermatology, 2017, 77, 623-633.	1.2	170
18	Towards global consensus on outcome measures for atopic eczema research: results of the <scp>HOME II</scp> meeting. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1111-1117.	5.7	169

#	Article	IF	Citations
19	Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes. Journal of Allergy and Clinical Immunology, 2016, 137, 130-136.	2.9	166
20	Is atopic disease a risk factor for attentionâ€deficit/hyperactivity disorder? A systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1506-1524.	5 . 7	156
21	Effects of Volatile Anesthetics on Mortality and Postoperative Pulmonary and Other Complications in Patients Undergoing Surgery. Anesthesiology, 2016, 124, 1230-1245.	2.5	156
22	Developmental comorbidity in attention-deficit/hyperactivity disorder. ADHD Attention Deficit and Hyperactivity Disorders, 2010, 2, 267-289.	1.7	151
23	Work Limitations and Productivity Loss Are Associated with Health-Related Quality of Life but Not with Clinical Severity in Patients with Psoriasis. Dermatology, 2006, 213, 102-110.	2.1	149
24	Atopic Eczema and Attention-Deficit/Hyperactivity Disorder in a Population-Based Sample of Children and Adolescents. JAMA - Journal of the American Medical Association, 2009, 301, 724.	7.4	145
25	Core Outcome Domains for Controlled Trials and Clinical Recordkeeping in Eczema: International Multiperspective Delphi Consensus Process. Journal of Investigative Dermatology, 2011, 131, 623-630.	0.7	143
26	Role of Depression in Quality of Life for Patients with Psoriasis. Dermatology, 2007, 215, 17-27.	2.1	141
27	Association of attention-deficit/hyperactivity disorder and atopic eczema modified by sleep disturbance in a large population-based sample. Journal of Epidemiology and Community Health, 2010, 64, 269-273.	3.7	141
28	Efficacy and safety of systemic treatments for moderateâ€toâ€severe psoriasis: metaâ€analysis of randomized controlled trials. British Journal of Dermatology, 2014, 170, 274-303.	1.5	141
29	Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement. British Journal of Dermatology, 2017, 176, 979-984.	1.5	141
30	Psychoendocrine and psychoneuroimmunological mechanisms in the comorbidity of atopic eczema and attention deficit/hyperactivity disorder. Psychoneuroendocrinology, 2013, 38, 12-23.	2.7	140
31	A consensus report on appropriate treatment optimization and transitioning in the management of moderateâ€toâ€severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 438-453.	2.4	122
32	Systemic Treatment of Severe Atopic Eczema: A Systematic Review. Acta Dermato-Venereologica, 2007, 87, 100-111.	1.3	120
33	Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). British Journal of Dermatology, 2016, 175, 69-79.	1.5	115
34	Safety and efficacy of thrombolysis in telestroke. Neurology, 2016, 87, 1344-1351.	1.1	113
35	Infant eczema, infant sleeping problems, and mental health at 10â€∫years of age: the prospective birth cohort study LISAplus. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 404-411.	5.7	111
36	Association between aircraft, road and railway traffic noise and depression in a large case-control study based on secondary data. Environmental Research, 2017, 152, 263-271.	7.5	109

#	Article	IF	Citations
37	Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial. British Journal of Dermatology, 2010, 162, 661-668.	1.5	108
38	Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis. JAMA Dermatology, 2020, 156, 659.	4.1	104
39	Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a populationâ€based sample. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 885-892.	2.4	102
40	Determinants of eczema: population-based cross-sectional study in Germany. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 206-213.	5.7	102
41	Harmonising Outcome Measures for Eczema (HOME).Report from the First International Consensus Meeting (HOME 1), 24 July 2010, Munich, Germany. British Journal of Dermatology, 2010, 163, 1166-1168.	1.5	101
42	Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). British Journal of Dermatology, 2014, 171, 1318-1325.	1.5	95
43	Allergy immunotherapy for allergic rhinitis effectively prevents asthma: Results from a large retrospective cohort study. Journal of Allergy and Clinical Immunology, 2015, 136, 1511-1516.	2.9	95
44	STandardisierte BerichtsROutine für SekundÃrdaten Analysen (STROSA) – ein konsentierter Berichtsstandard für Deutschland, Version 2. Gesundheitswesen, 2016, 78, e145-e160.	0.5	95
45	Infant-onset eczema in relation to mental health problems at age 10 years: Results from a prospective birth cohort study (German Infant Nutrition Intervention plus). Journal of Allergy and Clinical Immunology, 2010, 125, 404-410.	2.9	94
46	The European treatment of severe atopic eczema in children taskforce (TREAT) survey. British Journal of Dermatology, 2013, 169, 901-909.	1.5	94
47	Effects of structured patient education in adults with atopic dermatitis: Multicenter randomized controlled trial. Journal of Allergy and Clinical Immunology, 2017, 140, 845-853.e3.	2.9	87
48	Prevalence and treatment of hip and knee osteoarthritis in people aged 60 years or older in Germany: an analysis based on health insurance claims data. Clinical Interventions in Aging, 2018, Volume 13, 2339-2349.	2.9	87
49	Developing a core outcome domain set to assessing effectiveness of interdisciplinary multimodal pain therapy: the VAPAIN consensus statement on core outcome domains. Pain, 2018, 159, 673-683.	4.2	86
50	The Relationship Between Occupational Sun Exposure and Non-Melanoma Skin Cancer. Deutsches Ärzteblatt International, 2012, 109, 715-20.	0.9	85
51	Outdoor air pollution, green space, and cancer incidence in Saxony: a semi-individual cohort study. BMC Public Health, 2018, 18, 715.	2.9	84
52	Nonallergic comorbidities of atopic eczema: an overview of systematic reviews. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 37-45.	5.7	83
53	Albumin versus crystalloid solutions in patients with the acute respiratory distress syndrome: a systematic review and meta-analysis. Critical Care, 2014, 18, R10.	5.8	80
54	Understanding the relationship between objective disease severity, psoriatic symptoms, illness-related stress, health-related quality of life and depressive symptoms in patients with psoriasis — a structural equations modeling approach. General Hospital Psychiatry, 2007, 29, 134-140.	2.4	78

#	Article	IF	Citations
55	Regional responsibility and coordination of appropriate inpatient care capacities for patients with COVID-19 – the German DISPENSE model. PLoS ONE, 2022, 17, e0262491.	2.5	77
56	Atopic dermatitis displays stable and dynamic skin transcriptome signatures. Journal of Allergy and Clinical Immunology, 2021, 147, 213-223.	2.9	76
57	Occupational skin cancer induced by ultraviolet radiation and its prevention. British Journal of Dermatology, 2012, 167, 76-84.	1.5	7 5
58	Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. British Journal of Dermatology, 2008, 158, 351-359.	1.5	74
59	Association of Atopic Dermatitis with Cardiovascular Risk Factors and Diseases. Journal of Investigative Dermatology, 2017, 137, 1074-1081.	0.7	7 3
60	Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey. Journal of the American Academy of Dermatology, 2017, 76, 281-285.	1.2	73
61	Studying the post-COVID-19 condition: research challenges, strategies, and importance of Core Outcome Set development. BMC Medicine, 2022, 20, 50.	5.5	72
62	Systemic Immunomodulatory Treatments for Atopic Dermatitis. JAMA Dermatology, 2022, 158, 523.	4.1	70
63	A systematic review of the outcomes reported in multimodal pain therapy for chronic pain. European Journal of Pain, 2016, 20, 51-63.	2.8	68
64	Systemic treatments in the management of atopic dermatitis: A systematic review and metaâ€analysis. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1053-1076.	5.7	66
65	Psychiatric comorbidity in adult eczema. British Journal of Dermatology, 2009, 161, 878-883.	1.5	65
66	S2k‣eitlinie Neurodermitis [atopisches Ekzem; atopische Dermatitis] – Kurzversion. JDDG - Journal of the German Society of Dermatology, 2016, 14, 92-106.	0.8	65
67	Is ultraviolet exposure acquired at work the most important risk factor for cutaneous squamous cell carcinoma? Results of the population-based case-control study FB-181. British Journal of Dermatology, 2018, 178, 462-472.	1.5	62
68	S2k guideline on diagnosis and treatment of atopic dermatitis $\hat{a} \in$ " short version. Allergo Journal International, 2016, 25, 82-95.	2.0	60
69	Efficacy of systemic therapies for moderateâ€toâ€severe psoriasis: a systematic review and metaâ€analysis of longâ€term treatment. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 1331-1344.	2.4	58
70	Which Antipsoriatic Drug Has the Fastest Onset of Action?â€"Systematic Review on the Rapidity of the Onset of Action. Journal of Investigative Dermatology, 2013, 133, 1963-1970.	0.7	57
71	Comparison of different rating scales for the use in Delphi studies: different scales lead to different consensus and show different test-retest reliability. BMC Medical Research Methodology, 2020, 20, 28.	3.1	57
72	Psoriasis and Cardiometabolic Traits: Modest Association but Distinct Genetic Architectures. Journal of Investigative Dermatology, 2015, 135, 1283-1293.	0.7	56

#	Article	IF	CITATIONS
73	Measurement properties of adult qualityâ€ofâ€life measurement instruments for eczema: a systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 358-370.	5.7	56
74	Exploring relationships between in-hospital mortality and hospital case volume using random forest: results of a cohort study based on a nationwide sample of German hospitals, 2016–2018. BMC Health Services Research, 2022, 22, 1.	2.2	54
75	Occupational UV-Exposure is a Major Risk Factor for Basal Cell Carcinoma. Journal of Occupational and Environmental Medicine, 2018, 60, 36-43.	1.7	52
76	Recommended core outcome instruments for healthâ€related quality of life, longâ€term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*. British Journal of Dermatology, 2021, 185, 139-146.	1.5	52
77	Burden and risk factors of ambulatory or hospitalized CAP: AÂpopulation based cohort study. Respiratory Medicine, 2016, 121, 32-38.	2.9	51
78	The HOME Core outcome set for clinical trials of atopic dermatitis. Journal of Allergy and Clinical Immunology, 2022, 149, 1899-1911.	2.9	51
79	S2k guideline on diagnosis and treatment of atopic dermatitis – short version. JDDG - Journal of the German Society of Dermatology, 2016, 14, 92-105.	0.8	49
80	Delphi procedure in core outcome set development: rating scale and consensus criteria determined outcome selection. Journal of Clinical Epidemiology, 2019, 111, 23-31.	5.0	49
81	Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis––a multinational cross-sectional study. Archives of Dermatological Research, 2013, 305, 899-907.	1.9	48
82	Increased attentionâ€deficit/hyperactivity symptoms in atopic dermatitis are associated with history of antihistamine use. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 615-626.	5.7	48
83	Outdoor air pollution, greenspace, and incidence of ADHD: A semi-individual study. Science of the Total Environment, 2018, 642, 1362-1368.	8.0	48
84	What Do Patients Expect From Total Knee Arthroplasty? A Delphi Consensus Study on Patient Treatment Goals. Journal of Arthroplasty, 2017, 32, 2093-2099.e1.	3.1	47
85	Prenatal and Perinatal Risk Factors for Attention-Deficit/Hyperactivity Disorder. JAMA Pediatrics, 2012, 166, 1074.	3.0	46
86	Burden of soft-tissue and bone sarcoma in routine care. Cancer Epidemiology, 2015, 39, 440-446.	1.9	46
87	Indication Criteria for Total Knee Arthroplasty in Patients with Osteoarthritis – A Multi-perspective Consensus Study. Zeitschrift Fur Orthopadie Und Unfallchirurgie, 2017, 155, 539-548.	0.7	46
88	Evidence-based quality standards improve prognosis in colon cancerÂcare. European Journal of Surgical Oncology, 2018, 44, 1324-1330.	1.0	46
89	Navigating the landscape of core outcome set development in dermatology. Journal of the American Academy of Dermatology, 2019, 81, 297-305.	1.2	46
90	Early exposure to antibiotics and infections and the incidence of atopic eczema: A population-based cohort study. Pediatric Allergy and Immunology, 2010, 21, 292-300.	2.6	45

#	Article	IF	CITATIONS
91	Occupational polycyclic aromatic hydrocarbon exposure and risk of larynx cancer: a systematic review and meta-analysis. Occupational and Environmental Medicine, 2015, 72, 226-233.	2.8	45
92	What Factors are Important to Patients when Assessing Treatment Response: An International Cross-sectional Survey. Acta Dermato-Venereologica, 2017, 97, 86-90.	1.3	45
93	Ambulante Versorgung und medikamentöse Behandlung von Kindern und Erwachsenen mit atopischem Ekzem. JDDG - Journal of the German Society of Dermatology, 2009, 7, 345-352.	0.8	44
94	Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography. Experimental Dermatology, 2011, 20, 832-836.	2.9	44
95	The reliability of physical examination tests for the diagnosis of anterior cruciate ligament rupture – A systematic review. Manual Therapy, 2015, 20, 402-411.	1.6	42
96	Report from the kick-off meeting of the Cochrane Skin Group Core Outcome Set Initiative (CSG-COUSIN). British Journal of Dermatology, 2016, 174, 287-295.	1.5	41
97	Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1263-1272.	2.4	41
98	Berufliche Exposition gegenüber natürlicher UVâ€Strahlung und nichtâ€melanozytÃær Hautkrebs – ein systematischer Review zur Frage einer neuen Berufskrankheit. JDDG - Journal of the German Society of Dermatology, 2010, 8, 250-264.	0.8	40
99	Children and adolescents' health-related quality of life in relation to eczema, asthma and hay fever: results from a population-based cross-sectional study. Quality of Life Research, 2011, 20, 1295-1305.	3.1	40
100	Protective intraoperative ventilation with higher versus lower levels of positive end-expiratory pressure in obese patients (PROBESE): study protocol for a randomized controlled trial. Trials, 2017, 18, 202.	1.6	40
101	<scp>BASALIT</scp> trial: doubleâ€blind placeboâ€controlled allergen immunotherapy with <scp>rB</scp> et v 1â€ <scp>FV</scp> in birchâ€related soya allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1243-1253.	5.7	40
102	Determinants of treatment goals and satisfaction of patients with atopic eczema. JDDG - Journal of the German Society of Dermatology, 2008, 6, 458-465.	0.8	38
103	Electronic real-time assessment of patient-reported outcomes in routine care—first findings and experiences from the implementation in a comprehensive cancer center. Supportive Care in Cancer, 2016, 24, 3047-56.	2.2	38
104	Skincare interventions in infants for preventing eczema and food allergy: A cochrane systematic review and individual participant data metaâ€analysis. Clinical and Experimental Allergy, 2021, 51, 402-418.	2.9	38
105	Effects of the German skin cancer screening programme on melanoma incidence and indicators of disease severity. British Journal of Dermatology, 2016, 175, 912-919.	1.5	37
106	Assessing the relevance and uptake of core outcome sets (an agreed minimum collection of outcomes) Tj ETQqC	0.0 rgBT 1.9	/Oyerlock 10
107	Implementation of dupilumab in routine care of atopic eczema: results from the German national registry <scp>TREAT</scp> germany. British Journal of Dermatology, 2020, 183, 382-384.	1.5	37
108	Skin care interventions in infants for preventing eczema and food allergy. The Cochrane Library, 2021, 2021, CD013534.	2.8	37

#	Article	IF	CITATIONS
109	Different spreading dynamics throughout Germany during the second wave of the COVID-19 pandemic: a time series study based on national surveillance data. Lancet Regional Health - Europe, The, 2021, 6, 100151.	5.6	37
110	Development of a core outcome set for clinical trials in rosacea: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. Trials, 2016, 17, 429.	1.6	34
111	Outcome Assessment in Total Knee Arthroplasty: A Systematic Review and Critical Appraisal. Journal of Arthroplasty, 2017, 32, 653-665.e1.	3.1	34
112	Therapy Decision Support Based on Recommender System Methods. Journal of Healthcare Engineering, 2017, 2017, 1-11.	1.9	34
113	Depression and anxiety with exposure to ozone and particulate matter: An epidemiological claims data analysis. International Journal of Hygiene and Environmental Health, 2020, 228, 113562.	4.3	34
114	"Allergic mood―– Depressive and anxiety symptoms in patients with seasonal allergic rhinitis (SAR) and their association to inflammatory, endocrine, and allergic markers. Brain, Behavior, and Immunity, 2017, 65, 202-209.	4.1	33
115	Impact of the 13-Valent Pneumococcal Conjugate Vaccine on the Incidence of All-cause Pneumonia in Adults Aged ≥60 Years: A Population-based, Retrospective Cohort Study. Clinical Infectious Diseases, 2019, 68, 2117-2119.	5.8	33
116	How are eczema †flares†defined? A systematic review and recommendation for future studies. British Journal of Dermatology, 2014, 170, 548-556.	1.5	32
117	Chronic hand eczema in Germany: 5â€year followâ€up data from the CARPE registry. Contact Dermatitis, 2019, 80, 45-53.	1.4	32
118	Health risks in tobacco farm workers—a review of the literature. Zeitschrift Fur Gesundheitswissenschaften, 2007, 15, 255-264.	1.6	31
119	Determinants of disability, quality of life and depression in dermatological patients with systemic scleroderma. British Journal of Dermatology, 2012, 166, 343-353.	1.5	31
120	The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germany—Cross-Sectional Results of a Nationwide Observational Study (PROSa). Cancers, 2020, 12, 3590.	3.7	31
121	Core Outcome Set for Actinic Keratosis Clinical Trials. JAMA Dermatology, 2020, 156, 326.	4.1	31
122	The moderating role of allergy immunotherapy in asthma progression: Results of a populationâ€based cohort study. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 596-602.	5.7	30
123	Update "Systemic treatment of atopic dermatitis―of the S2kâ€guideline on atopic dermatitis. JDDG - Journal of the German Society of Dermatology, 2021, 19, 151-168.	0.8	30
124	Validation and application of a core set of patient-relevant outcome domains to assess the effectiveness of multimodal pain therapy (VAPAIN): a study protocol. BMJ Open, 2015, 5, e008146-e008146.	1.9	29
125	Core outcome sets in dermatology: report from the second meeting of the International Cochrane Skin Group Core Outcome Set Initiative. British Journal of Dermatology, 2018, 178, e279-e285.	1.5	29
126	<scp>TRE</scp> atment of <scp>AT</scp> opic eczema (<scp>TREAT</scp>) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries. British Journal of Dermatology, 2019, 181, 492-504.	1.5	29

#	Article	IF	Citations
127	Cochrane Reviews and Dermatological Trials Outcome Concordance: Why Core Outcome Sets Could Make Trial Results More Usable. Journal of Investigative Dermatology, 2019, 139, 1045-1053.	0.7	29
128	Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative. Journal of the American Academy of Dermatology, 2020, 82, 1181-1186.	1.2	29
129	The Incidence and Determinants of Decubitus Ulcers in Hospital Care. Deutsches Ärzteblatt International, 2013, 110, 550-6.	0.9	29
130	Which factors predict incident pressure ulcers in hospitalized patients? A prospective cohort study. British Journal of Dermatology, 2014, 170, 1285-1290.	1.5	27
131	Systematic review and meta-analysis of randomised controlled clinical trial evidence refutes relationship between pharmacotherapy with angiotensin-receptor blockers and an increased risk of cancer. European Journal of Internal Medicine, 2019, 64, 1-9.	2.2	27
132	Use of Patient-Reported Outcome Measures and Patient-Reported Experience Measures Within Evaluation Studies of Telemedicine Applications: Systematic Review. Journal of Medical Internet Research, 2021, 23, e30042.	4.3	27
133	Leflunomide as a novel treatment option in severe atopic dermatitis. British Journal of Dermatology, 2004, 150, 1182-1185.	1.5	26
134	Chronic pruritus associated with dermatologic disease in infancy and childhood: Update from an interdisciplinary group of dermatologists and pediatricians. Pediatric Allergy and Immunology, 2013, 24, 527-539.	2.6	26
135	<scp>TRE</scp> atment of <scp>AT</scp> opic eczema (<scp>TREAT</scp>) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo―and systemic therapy registries. British Journal of Dermatology, 2019, 180, 790-801.	1.5	26
136	Do certified cancer centers provide more costâ€effective care? A health economic analysis of colon cancer care in Germany using administrative data. International Journal of Cancer, 2021, 149, 1744-1754.	5.1	26
137	Medical care and treatment of allergic rhinitis: a population-based cohort study based on routine healthcare utilization data. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 850-858.	5.7	25
138	Myelodysplastic syndromes and bone loss in mice and men. Leukemia, 2017, 31, 1003-1007.	7.2	25
139	Usage and effectiveness of systemic treatments in adults with severe atopic eczema: First results of the German Atopic Eczema Registry TREATgermany. JDDG - Journal of the German Society of Dermatology, 2017, 15, 49-59.	0.8	25
140	The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: An Initiative to Harmonize Data Collection across National Atopic Eczema Photo- and Systemic Therapy Registries. Journal of Investigative Dermatology, 2017, 137, 2014-2016.	0.7	25
141	Standardized reporting of the Eczema Area and Severity Index (EASI) and the Patient-Oriented Eczema Measure (POEM): a recommendation by the Harmonising Outcome Measures for Eczema (HOME) Initiative. British Journal of Dermatology, 2018, 179, 540-541.	1.5	25
142	The European TREatment of ATopic eczema (TREAT) Registry Taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderateâ€toâ€severe atopic eczema*. British Journal of Dermatology, 2020, 183, 1073-1082.	1.5	25
143	Validation of Treatment Escalation as a Definition of Atopic Eczema Flares. PLoS ONE, 2015, 10, e0124770.	2.5	24
144	Outpatient care and medical treatment of children and adults with atopic eczema. JDDG - Journal of the German Society of Dermatology, 2009, 7, 345-351.	0.8	23

#	Article	IF	Citations
145	Altered performance in attention tasks in patients with seasonal allergic rhinitis: seasonal dependency and association with disease characteristics. Psychological Medicine, 2015, 45, 1289-1299.	4.5	23
146	The reliability of physical examination tests for the clinical assessment of scapular dyskinesis in subjects with shoulder complaints: A systematic review. Physical Therapy in Sport, 2017, 26, 64-89.	1.9	23
147	The influence of cross-sectoral treatment models on patients with mental disorders in Germany: study protocol of a nationwide long-term evaluation study (EVA64). BMC Psychiatry, 2018, 18, 139.	2.6	23
148	Basal cell carcinoma risk and solar UV exposure in occupationally relevant anatomic sites: do histological subtype, tumor localization and Fitzpatrick phototype play a role? A population-based case-control study. Journal of Occupational Medicine and Toxicology, 2020, 15, 28.	2.2	23
149	Reliability of specific physical examination tests for the diagnosis of shoulder pathologies: a systematic review and meta-analysis. British Journal of Sports Medicine, 2017, 51, 511-518.	6.7	22
150	Cancer patients' control preferences in decision making and associations with patient-reported outcomes: a prospective study in an outpatient cancer center. Supportive Care in Cancer, 2017, 25, 2753-2760.	2.2	22
151	Patterns of chronic hand eczema: a semantic map analysis of the <scp>CARPE</scp> registry data. British Journal of Dermatology, 2018, 178, 229-237.	1.5	22
152	Topical treatments for scalp psoriasis: summary of a Cochrane Systematic Review. British Journal of Dermatology, 2017, 176, 604-614.	1.5	21
153	TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries. Trials, 2017, 18, 87.	1.6	21
154	Development of a core outcome set for clinical trials in basal cell carcinoma: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. Trials, 2017, 18, 490.	1.6	21
155	Is treatment in certified cancer centers related to better survival in patients with pancreatic cancer? Evidence from a large German cohort study. BMC Cancer, 2022, 22, .	2.6	21
156	CARPE: ein Registerprojekt der Deutschen Dermatologischen Gesellschaft (DDG) zur Charakterisierung und Versorgung des chronischen Handekzems. JDDG - Journal of the German Society of Dermatology, 2011, 9, 682-689.	0.8	20
157	Interventions for mycosis fungoides. The Cochrane Library, 2012, , CD008946.	2.8	20
158	Allergies in Germany $\hat{a} \in$ prevalence and perception by the public. JDDG - Journal of the German Society of Dermatology, 2013, 11, 514-520.	0.8	20
159	Standardization of double blind placebo controlled food challenge with soy within a multicentre trial. Clinical and Translational Allergy, 2016, 6, 39.	3.2	20
160	Effectiveness of Global Treatment Budgets for Patients With Mental Disordersâ€"Claims Data Based Meta-Analysis of 13 Controlled Studies From Germany. Frontiers in Psychiatry, 2020, 11, 131.	2.6	20
161	Are patients benefiting from participation in the German skin cancer screening programme? A large cohort study based on administrative data. British Journal of Dermatology, 2022, 186, 69-77.	1.5	20
162	Effectiveness of Inpatient Treatment on Quality of Life and Clinical Disease Severity in Atopic Dermatitis and Psoriasis Vulgaris – A Prospective Study. Dermatology, 2007, 214, 68-76.	2.1	19

#	Article	IF	Citations
163	Correlation between Dermatology Life Quality Index (DLQI) scores and Work Limitations Questionnaire (WLQ) allows the calculation of percent work productivity loss in patients with psoriasis. Archives of Dermatological Research, 2015, 307, 451-453.	1.9	19
164	Memory and multitasking performance during acute allergic inflammation in seasonal allergic rhinitis. Clinical and Experimental Allergy, 2017, 47, 479-487.	2.9	19
165	Impact of pneumococcal polysaccharide vaccine on incidence and mortality after pneumonia in adults aged ≥60 years—a population-based retrospective cohort study. Clinical Microbiology and Infection, 2018, 24, 500-504.	6.0	19
166	Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature. Biologics: Targets and Therapy, 2009, 3, 303-18.	3.2	19
167	Interrater reliability of the modified scapular assistance test withÂandÂwithout handheld weights. Manual Therapy, 2015, 20, 868-874.	1.6	18
168	Core outcome sets in dermatology: report from the second meeting of the International Cochrane Skin Group Core Outcome Set Initiative. British Journal of Dermatology, 2018, 178, e297-e297.	1.5	18
169	Determinants of hospitalization and length of stay among people with dementia – An analysis of statutory health insurance claims data. Archives of Gerontology and Geriatrics, 2018, 76, 227-233.	3.0	18
170	Altered hypothalamus-pituitary-adrenal axis function: A relevant factor in the comorbidity of atopic eczema and attention deficit/hyperactivity disorder?. Psychoneuroendocrinology, 2019, 105, 178-186.	2.7	18
171	Are birth outcomes in low risk birth cohorts related to hospital birth volumes? A systematic review. BMC Pregnancy and Childbirth, 2021, 21, 531.	2.4	18
172	Impact of birthweight on health-care utilization during early childhood – a birth cohort study. BMC Pediatrics, 2019, 19, 69.	1.7	17
173	Outcomes for Pressure Ulcer Trials (OUTPUTs) project: review and classification of outcomes reported in pressure ulcer prevention research. British Journal of Dermatology, 2021, 184, 617-626.	1.5	17
174	Elevated NK-cell transcriptional signature and dysbalance of resting and activated NK cells in atopic dermatitis. Journal of Allergy and Clinical Immunology, 2021, 147, 1959-1965.e2.	2.9	17
175	Blood transcriptome profiling identifies 2 candidate endotypes of atopic dermatitis. Journal of Allergy and Clinical Immunology, 2022, 150, 385-395.	2.9	17
176	Effectiveness of Interdisciplinary vs. Dermatological Care of Moderate- to-severe Psoriasis: A Pragmatic Randomised Controlled Trial. Acta Dermato-Venereologica, 2014, 94, 192-197.	1.3	16
177	Disease Burden of Patients With Osteoarthritis: Results of a Crossâ€Sectional Survey Linked to Claims Data. Arthritis Care and Research, 2020, 72, 193-200.	3.4	16
178	Multiperspective and Multimethod Evaluation of Flexible and Integrative Psychiatric Care Models in Germany: Study Protocol of a Prospective, Controlled Multicenter Observational Study (PsychCare). Frontiers in Psychiatry, 2021, 12, 659773.	2.6	16
179	Outcome assessment in dermatology clinical trials and cochrane reviews: call for a dermatologyâ€specific outcome taxonomy. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 523-535.	2.4	15
180	Skin Barrier and Inflammation Genes Associated with Atopic Dermatitis are Regulated by Interleukin-13 and Modulated by Tralokinumab In vitro. Acta Dermato-Venereologica, 2021, 101, adv00447.	1.3	15

#	Article	IF	CITATIONS
181	Treatment Following an Evidence-Based Algorithm versus Individualised Symptom-Oriented Treatment for Atopic Eczema. Dermatology, 2008, 217, 299-308.	2.1	14
182	Itches and scratches – is there a link between eczema, ADHD, sleep disruption and food hypersensitivity?. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 1407-1409.	5.7	14
183	Measurement of healthcare quality in atopic dermatitis $\hat{a}\in$ development and application of a set of quality indicators. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 2237-2243.	2.4	14
184	Guideline-based quality indicators—a systematic comparison of German and international clinical practice guidelines. Implementation Science, 2019, 14, 71.	6.9	14
185	TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema. British Journal of Dermatology, 2020, 182, 1423-1429.	1.5	14
186	Status report on the atopic dermatitis registry TREATgermany. Allergologie Select, 2021, 5, 274-286.	3.1	14
187	Occupational exposure to nonâ€artificial UVâ€light and nonâ€melanocytic skin cancer – a systematic review concerning a new occupational disease. JDDG - Journal of the German Society of Dermatology, 2010, 8, 250-263.	0.8	13
188	Core Outcome Sets and Multidimensional Assessment Tools for Harmonizing Outcome Measure in Chronic Pain and Back Pain. Healthcare (Switzerland), 2016, 4, 63.	2.0	13
189	Patients with soft tissue sarcoma comprise a higher probability of comorbidities than cancer-free individuals. A secondary data analysis. European Journal of Cancer Care, 2017, 26, e12605.	1.5	13
190	A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal. British Journal of Dermatology, 2017, 177, 999-1003.	1.5	13
191	Development of a core outcome set for clinical trials in squamous cell carcinoma: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. Trials, 2017, 18, 321.	1.6	13
192	Development of a core outcome set for clinical trials in facial aging: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. Trials, 2017, 18, 359.	1.6	13
193	Assessing uptake of the Harmonising Outcome Measures for Eczema (HOME) Core Outcome Set and recommended instruments. British Journal of Dermatology, 2020, 183, 566-568.	1.5	13
194	Utilization of Interdisciplinary Tumor Boards for Sarcoma Care in Germany: Results from the PROSa Study. Oncology Research and Treatment, 2021, 44, 301-312.	1,2	13
195	Measurement properties of adult quality-of-life measurement instruments for eczema: protocol for a systematic review. Systematic Reviews, 2015, 4, 48.	5.3	12
196	Severity and functional disability of patients with occupational contact dermatitis: validation of the German version of the Occupational Contact Dermatitis Disease Severity Index. Contact Dermatitis, 2015, 72, 84-89.	1.4	12
197	Patient-Reported Outcomes and Outcome Predictors after Primary Total Hip Arthroplasty: Results from the Dresden Hip Surgery Registry. HIP International, 2016, 26, 73-81.	1.7	12
198	Systemic immunomodulatory treatments for atopic dermatitis: protocol for a systematic review with network meta-analysis. BMJ Open, 2018, 8, e023061.	1.9	12

#	Article	IF	CITATIONS
199	Guideline-based quality indicatorsâ€"a systematic comparison of German and international clinical practice guidelines: protocol for a systematic review. Systematic Reviews, 2018, 7, 5.	5.3	12
200	Which disease-related factors influence patients' and physicians' willingness to consider joint replacement in hip and knee OA? Results of a questionnaire survey linked to claims data. BMC Musculoskeletal Disorders, 2020, 21, 352.	1.9	12
201	Interventions for mycosis fungoides. The Cochrane Library, 2020, 7, CD008946.	2.8	12
202	The Organic Turn: Coping With Pandemic and Non-pandemic Challenges by Integrating Evidence-, Theory-, Experience-, and Context-Based Knowledge in Advising Health Policy. Frontiers in Public Health, 2021, 9, 727427.	2.7	12
203	Feasibility of a Multimodal Telemedical Intervention for Patients with Parkinson's Diseaseâ€"A Pilot Study. Journal of Clinical Medicine, 2022, 11, 1074.	2.4	12
204	Prediction of inpatient pressure ulcers based on routine healthcare data using machine learning methodology. Scientific Reports, 2022, 12, 5044.	3.3	12
205	Alternative Models of Comorbidity: A Framework for the Interpretation of Epidemiological Association Studies. Journal of Investigative Dermatology, 2014, 134, 303-307.	0.7	11
206	Impact of regionalisation and case-volume on neonatal and perinatal mortality: an umbrella review. BMJ Open, 2020, 10, e037135.	1.9	11
207	Implementation of patient-reported outcome assessment in routine cancer care: A systematic review of multicentric programs in Europe. Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen, 2020, 156-157, 11-23.	0.9	11
208	Do drugâ€related safety warnings have the expected impact on drug therapy? A systematic review. Pharmacoepidemiology and Drug Safety, 2020, 29, 229-251.	1.9	11
209	Reaching clinically relevant outcome measures for new pharmacotherapy and immunotherapy of atopic eczema. Current Opinion in Allergy and Clinical Immunology, 2015, 15, 227-233.	2.3	10
210	Early comprehensive care of preterm infantsâ€"effects on quality of life, childhood development, and healthcare utilization: study protocol for a cohort study linking administrative healthcare data with patient reported primary data. BMC Pediatrics, 2016, 16, 104.	1.7	10
211	Measuring long-term disease control in patients with atopic dermatitis: AÂvalidation study of well-controlled weeks. Journal of Allergy and Clinical Immunology, 2017, 140, 1580-1586.	2.9	10
212	Core outcome sets in dermatology: next steps. British Journal of Dermatology, 2018, 179, 549-550.	1.5	10
213	Implementing longitudinal integrated curricula: Systematic review of barriers and facilitators. Medical Education, 2021, 55, 558-573.	2.1	10
214	Financial toxicity in sarcoma patients and survivors in Germany: results from the multicenter PROSa study. Supportive Care in Cancer, 2022, 30, 187-196.	2.2	10
215	ADHD in schoolâ€age children is related to infant exposure to systemic H1â€antihistamines. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2956-2957.	5.7	10
216	Total hip replacement for osteoarthritis. Deutsches Ärzteblatt International, 2021, , .	0.9	10

#	Article	IF	Citations
217	Effektivitädes Hautkrebsscreenings für die Altersgruppe der 14â€bis 34â€Järigen â€" Ergebnisse eines Modellvorhabens aus Sachsen. JDDG - Journal of the German Society of Dermatology, 2011, 9, 608-617.	0.8	9
218	Implementation of a mobile inpatient quality of life (QoL) assessment for oncology nursing. Supportive Care in Cancer, 2016, 24, 3391-3399.	2.2	9
219	Cost-effectiveness of systemic treatments for moderate-to-severe psoriasis in the German health care setting. Archives of Dermatological Research, 2016, 308, 249-261.	1.9	9
220	Associations of myeloid hematological diseases of the elderly with osteoporosis: A longitudinal analysis of routine health care data. Leukemia Research, 2018, 69, 81-86.	0.8	9
221	Outcomes for Pressure Ulcer Trials (OUTPUTs): protocol for the development of a core domain set for trials evaluating the clinical efficacy or effectiveness of pressure ulcer prevention interventions. Trials, 2019, 20, 449.	1.6	9
222	Implementation and first results of a tablet-based assessment referring to patient-reported outcomes in an inpatient cancer care unit. Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen, 2017, 121, 64-72.	0.9	8
223	Quality Measurement Recommendations Relevant to Clinical Guidelines in Germany and the United Kingdom: (What) Can We Learn From Each Other?. Inquiry (United States), 2018, 55, 004695801876149.	0.9	8
224	Targeted and Checkpoint Inhibitor Therapy of Metastatic Malignant Melanoma in Germany, 2000–2016. Cancers, 2020, 12, 2354.	3.7	8
225	Can we trust the standardized mortality ratio? A formal analysis and evaluation based on axiomatic requirements. PLoS ONE, 2021, 16, e0257003.	2.5	8
226	Atopic dermatitis: disease characteristics and comorbidities in smoking and nonâ€smoking patients from the TREATgermany registry. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 413-421.	2.4	8
227	Auswirkungen der Einfýhrung der Praxisgebühr auf die ambulante Versorgung und Therapie von Patienten mit atopischem Ekzem. JDDG - Journal of the German Society of Dermatology, 2009, 7, 879-887.	0.8	7
228	National and multinational guidelines in Europe: results from an online survey on awareness of different national and European psoriasis guidelines. Archives of Dermatological Research, 2013, 305, 637-643.	1.9	7
229	Occupational skin cancer due to UVâ€irradiation – Analyses of notified cases as "virtuallyâ€certain― occupational disease in Germany between 2005 and 2011. JDDG - Journal of the German Society of Dermatology, 2014, 12, 491-497.	0.8	7
230	Beruflicher Hautkrebs durch UVâ€Strahlung – Analyse der Verdachtsmeldungen und Anerkennungen einer "Wieâ€BK" nach § 9 Abs. 2 SGB VII der Jahre 2005 bis 2011 in Deutschland. JDDG - Journal of the German Society of Dermatology, 2014, 12, 491-498.	0.8	7
231	The German national consensus on wound documentation and outcomes: Rationale, working programme and current status. Wound Medicine, 2014, 7, 8-13.	2.7	7
232	The stroke east <scp>S</scp> axony pilot project for organized postâ€stroke care: a case–control study. Brain and Behavior, 2016, 6, e00455.	2.2	7
233	Einsatz und Wirksamkeit von Systemtherapien bei Erwachsenen mit schwerer Neurodermitis: Erste Ergebnisse des deutschen Neurodermitisâ€Registers TREATgermany. JDDG - Journal of the German Society of Dermatology, 2017, 15, 49-60.	0.8	7
234	Recommended core outcome instruments for healthâ€related quality of life, longâ€term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. British Journal of Dermatology, 2020, 185, 139.	1.5	7

#	Article	lF	CITATIONS
235	Development of a core outcome set for cutaneous squamous cell carcinoma trials: identification of core domains and outcomes*. British Journal of Dermatology, 2021, 184, 1113-1122.	1.5	7
236	Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Crossâ€sectional results of a German multicentre observational study (PROSa). European Journal of Cancer Care, 2021, 30, e13484.	1.5	7
237	eCross-cultural adaptation of the spine oncology-specific SOSGOQ2.0 questionnaire to German language and the assessment of its validity and reliability in the clinical setting. BMC Cancer, 2021, 21, 1044.	2.6	7
238	An individualized decision aid for physicians and patients for total knee replacement in osteoarthritis (Value-based TKR study): study protocol for a multi-center, stepped wedge, cluster randomized controlled trial. BMC Musculoskeletal Disorders, 2021, 22, 783.	1.9	7
239	Dose or content? Effectiveness of pain rehabilitation programs for patients with chronic low back pain: A systematic review. Waterschoot et al., Pain 155 (2014) 179–189. Pain, 2014, 155, 1903-1904.	4.2	6
240	Health utilities for controlled and uncontrolled chronic hand eczema in healthcare employees. Contact Dermatitis, 2018, 78, 18-27.	1.4	6
241	Effectiveness of the IQM peer review procedure to improve in-patient care—a pragmatic cluster randomized controlled trial (IMPRESS): study design and baseline results. Zeitschrift Fur Gesundheitswissenschaften, 2021, 29, 195-203.	1.6	6
242	Postinflammatory hyperpigmentation: protocol for development of a core outcome set for clinical trials. Archives of Dermatological Research, 2022, 314, 357-361.	1.9	6
243	Lifetime prevalence and determinants of hand eczema in an adolescent population in Germany: 15â€year followâ€up of the LISA cohort study. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 547-556.	2.4	6
244	The association of Health-Related Quality of Life and 1-year-survival in sarcoma patientsâ€"results of a Nationwide Observational Study (PROSa). British Journal of Cancer, 2022, 126, 1346-1354.	6.4	6
245	Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature. Biologics: Targets and Therapy, 2009, , 303.	3.2	5
246	Effectiveness of skin cancer screening for individuals age 14 to 34 years. JDDG - Journal of the German Society of Dermatology, 2011, 9, 608-616.	0.8	5
247	Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology, 2013, 68, 1040-1041.	1.2	5
248	Satisfaction with medical treatment in patients with hand dermatitis – a crossâ€sectional study. JDDG - Journal of the German Society of Dermatology, 2013, 11, 1007-1013.	0.8	5
249	Which factors are associated with the use of systemic antihistamines in patients with chronic hand eczema? Results from the <scp>CARPE</scp> registry. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 50-56.	2.4	5
250	Health utilities for chronic low back pain. Journal of Occupational Medicine and Toxicology, 2017, 12, 28.	2.2	5
251	Current State of Sarcoma Care in Germany: Results of an Online Survey of Physicians. Oncology Research and Treatment, 2019, 42, 589-598.	1.2	5
252	Ranking hospitals when performance and risk factors are correlated: A simulation-based comparison of risk adjustment approaches for binary outcomes. PLoS ONE, 2019, 14, e0225844.	2.5	5

#	Article	IF	CITATIONS
253	Controversy and Debate Series on Core Outcome Sets. Paper 6: Improving the generalizability, credibility and implementation of core outcome sets – the example of the Cochrane Skin-Core Outcome Set Initiative (CS-COUSIN). Journal of Clinical Epidemiology, 2020, 125, 229-231.	5.0	5
254	Health-related quality of life in elderly, multimorbid individuals with and without depression and/or mild cognitive impairment using a telemonitoring application. Quality of Life Research, 2021, 30, 2829-2841.	3.1	5
255	Evidenzbasierte Qualit $\tilde{A}^{\rm E}$ smessung als Voraussetzung f $\tilde{A}^{1}\!\!/\!\!4$ r Value-based Healthcare. Monitor Versorgungsforschung, 2015, 8, 49-54.	0.0	5
256	A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease. Programme Grants for Applied Research, 2016, 4, 1-488.	1.0	5
257	Durch UV-Strahlung induzierte bösartige Hauttumoren – Erarbeitung und Evaluation von versicherungsrechtlich relevanten Abgrenzungskriterien beruflicher gegenüber nicht beruflicher Verursachung. Wissenschaftlicher Abschlussbericht des DGUV Dermatologie in Beruf Und Umwelt, 2014. 62. 107-132.	0.5	5
258	Evaluation of a flexible and integrative psychiatric care model in a department of child and adolescent psychiatry in TÃ $\frac{1}{4}$ bingen, Germany: study protocol (EVA_TIBAS). BMC Health Services Research, 2021, 21, 1262.	2.2	5
259	Development of a core outcome set for basal cell carcinoma. Journal of the American Academy of Dermatology, 2022, 87, 573-581.	1.2	5
260	Outcome Measures, Case Definition, and Nomenclature Are All Important and Distinct Aspects of Atopic Eczema: A Call for Harmonization. Journal of Investigative Dermatology, 2012, 132, 473-474.	0.7	4
261	Effects of systemic immunosuppressive therapies for moderate-to-severe eczema in children and adults. The Cochrane Library, 2015, , .	2.8	4
262	Patient-Level and Hospital-Level Risk Factors for In-Hospital Mortality in Patients Ventilated for More Than 24 Hours: Results of a Nationwide Cohort Study. Journal of Intensive Care Medicine, 2020, 36, 088506662094218.	2.8	4
263	International experiences in the development and implementation of guideline-based quality indicators: a qualitative study. BMJ Open, 2021, 11, e039770.	1.9	4
264	Independent Use of a Home-Based Telemonitoring App by Older Patients With Multimorbidity and Mild Cognitive Impairment: Qualitative Study. JMIR Human Factors, 2021, 8, e27156.	2.0	4
265	A pharmaceutical therapy recommender system enabling shared decision-making. User Modeling and User-Adapted Interaction, 2022, 32, 1019-1062.	3.8	4
266	Potentials and current shortcomings in the cooperation between German centers for rare diseases and primary care physicians: results from the project TRANSLATE-NAMSE. Orphanet Journal of Rare Diseases, 2021, 16, 494.	2.7	4
267	Protocol for development of a core outcome set for clinical trials in melasma. BMJ Open, 2022, 12, e046953.	1.9	4
268	Effects of the introduction of the German "Praxisgebýhr―on outpatient care and treatment of patients with atopic eczema. JDDG - Journal of the German Society of Dermatology, 2009, 7, 879-886.	0.8	3
269	Methotrexate use and liver disease - a causal relationship?. British Journal of Dermatology, 2014, 171, 6-7.	1.5	3
270	Clearing up misunderstandings around core outcomes for atopic dermatitis. British Journal of Dermatology, 2015, 173, 623-624.	1.5	3

#	Article	IF	Citations
271	Physical tests for diagnosing anterior cruciate ligament rupture. The Cochrane Library, 0, , .	2.8	3
272	Individual-Level Linkage of Primary and Secondary Data from Three Sources for Comprehensive Analyses of Low Birthweight Effects. Gesundheitswesen, 2020, 82, S108-S116.	0.5	3
273	Healthcare costs associated with allergic rhinitis, asthma allergy immunotherapy. European Annals of Allergy and Clinical Immunology, 2019, 52, 164-174.	1.0	3
274	Medical Care and Survival of Soft-Tissue and Bone Sarcoma Patients: Results and Methodological Aspects of a German Subnational Cohort Study Based on Administrative Healthcare Data. Oncology Research and Treatment, 2021, 44, 103-110.	1.2	3
275	Implementation and Effectiveness of Novel Therapeutic Substances for Advanced Malignant Melanoma in Saxony, Germany, 2010–2020—Cohort Study Based on Administrative Data. Cancers, 2021, 13, 6150.	3.7	3
276	Perception of the coronavirus pandemic by patients with atopic dermatitis – Results from the TREATgermany registry. JDDG - Journal of the German Society of Dermatology, 2022, 20, 45-57.	0.8	3
277	Cardiovascular Risk Factors and Psychiatric Comorbidity in Patients with Atopic Eczema: A Population-Based Case-Control Study. Dermatitis, 2008, 19, 218-238.	1.6	2
278	Treatment satisfaction and health status in patients with systemic sclerosis. JDDG - Journal of the German Society of Dermatology, 2012, 10, 905-911.	0.8	2
279	Behandlungszufriedenheit von Patienten mit Handekzem — eine Querschnittstudie. JDDG - Journal of the German Society of Dermatology, 2013, 11, 1007-1015.	0.8	2
280	Application of recommender system methods for therapy decision support., 2016,,.		2
281	Prenatal methamphetamine exposure: effects on child development Deutsches Ärzteblatt International, 2021, 118, 313-319.	0.9	2
282	Verminderte berufliche LeistungsfÄ ¤ igkeit und Lebensqualitäbei Patient/innen mit moderater bis schwerer Neurodermitis – Ergebnisse aus dem Deutschen Neurodermitisregister TREATgermany. Allergologie, 2019, 42, 266-274.	0.1	2
283	Effect of clinical peer review on mortality in patients ventilated for more than 24 hours: a cluster randomised controlled trial. BMJ Quality and Safety, 2022, , bmjqs-2021-013864.	3.7	2
284	Indication Criteria for Total Hip Arthroplasty in Patients with Hip Osteoarthritis—Recommendations from a German Consensus Initiative. Medicina (Lithuania), 2022, 58, 574.	2.0	2
285	Pressure ulcer prevention - more than a problem of documentation? An Evidence-based approach. Safety in Health, $2015,1,.$	0.7	1
286	After the approval of dupilumab for moderate-to-severe atopic dermatitis: what is next on the research agenda?. British Journal of Dermatology, 2018, 178, 992-993.	1.5	1
287	Impact of Complex Quality-Interventions on Patient Outcome: A Systematic Overview of Systematic Reviews. Inquiry (United States), 2019, 56, 004695801988418.	0.9	1
288	Impact of safety warnings for fluoroquinolones on prescribing behaviour. Results of a cohort study with outpatient routine data. Infection, 2021, 49, 447-455.	4.7	1

#	Article	IF	CITATIONS
289	Komorbiditävon Neurodermitis und Aufmerksamkeits-Defizit/Hyperaktivitäs- Störung. Mögliche psychoneuroimmunologische Ursachen und aktuelle Forschungsfragen. Allergologie, 2015, 38, 236-243.	0.1	1
290	Präatale Methamphetamin Exposition (PME). Suchttherapie, 2019, 20, .	0.1	1
291	Atopic dermatitis and depressive symptoms. Results of the German national AD Registry TREATgermany. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	1
292	A Qualitative Needs Analysis of Skin Cancer Care from the Perspectives of Patients, Physicians, and Health Insurance Representatives—A Case Study from Eastern Saxony, Germany. Current Oncology, 2022, 29, 2583-2598.	2.2	1
293	Shifting focus from "what we do―to the "impact of what we do― Application of outcome measures to routine clinical care in dermatology. Journal of the American Academy of Dermatology, 2022, 87, e83-e84.	1.2	1
294	Determinanten aktiver GesundheitsfĶrderung. Pravention Und Gesundheitsforderung, 2009, 4, 225-226.	1.5	0
295	Commentary: eczema and cancer risk. British Journal of Dermatology, 2011, 165, 463-464.	1.5	О
296	Translation and cross-cultural adaptation of the Nordic Occupational Skin Questionnaire (NOSQ-2002) to German. Journal of Occupational Medicine and Toxicology, 2014, 9, .	2.2	O
297	Severity And Functional Disability Of Patients With Occupational Contact Dermatitis: Validation Of The German Version Of The Occupational Contact Dermatitis Disease Severity Index (ODDI). Value in Health, 2014, 17, A567.	0.3	О
298	Trials are meaningful for clinical decision making only when their endpoints are valid and comparable. British Journal of Dermatology, 2015, 172, 1175-1177.	1.5	0
299	Response to Ruan etÂal., <scp>EJP</scp> 2016. European Journal of Pain, 2016, 20, 1545-1546.	2.8	O
300	Editorial: Patient First: Wer ist der Patient und wie wird er in der Gesundheitsversorgung beteiligt?. Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen, 2017, 121, 52-53.	0.9	0
301	Reply to Theilacker et al. Clinical Infectious Diseases, 2020, 70, 2457-2458.	5.8	O
302	Only the best instruments should be used to measure core outcomes. British Journal of Dermatology, 2021, 185, 3-4.	1.5	0
303	Impact of TSPO polymorphism on [18F]GE-180binding in healthy and pseudoreference tissue of neurooncological and neurodegenerative disorders. Nuklearmedizin - NuclearMedicine, 2021, 60, .	0.7	O
304	Forschungsprojekt "Durch UVStrahlung induzierte bösartige Hauttumore" – Berufliche und auÄŸerberufliche Exposition gegenÃ⅓ber UV-Strahlung und Hautkrebs. Dermatologie in Beruf Und Umwelt, 2017, 65, 13-14.	0.5	0
305	Effects of systemic immunosuppressive therapies for moderate-to-severe eczema in children and adults. The Cochrane Library, 0, , .	2.8	O
306	Prevention in Metalworkers., 2020,, 1655-1662.		0

#	Article	IF	CITATIONS
307	Eczema. Clinical Evidence, 2011, 2011, .	0.2	O
	Impact of the COVID-19 pandemic on coloractal cancer (CPC) care: Data from 22 Cerman cancer centers	•	

Impact of the COVID-19 pandemic on colorectal cancer (CRC) care: Data from 22 German cancer centers (CC) and the Institute of Pathology, Ruhr-University Bochum - the AIO (Working Group for Internal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Clinical Oncology, 2022, 40, 3626-3626.